Pure Global

VAT00008: A parallel-group, Phase III, multi-stage, modified double-blind, Placebo-Controlled, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent- CoV2 preS dTM-AS03 (D614) and bivalent CoV2 preS dTM-AS03 (D614 + B.1.351)) for prevention against COVID-19 in adults 18 years of age and older. - Trial SLCTR_2021_026

Access comprehensive clinical trial information for SLCTR_2021_026 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sanofi Pasteur Inc. and is currently status unknown. The study focuses on COVID-19.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2021_026
Phase 3
Trial Details
Sri Lanka Clinical Trials Registry โ€ข SLCTR_2021_026
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
VAT00008: A parallel-group, Phase III, multi-stage, modified double-blind, Placebo-Controlled, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent- CoV2 preS dTM-AS03 (D614) and bivalent CoV2 preS dTM-AS03 (D614 + B.1.351)) for prevention against COVID-19 in adults 18 years of age and older.
A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older

Study Focus

COVID-19

Interventional

Sponsor & Location

Sanofi Pasteur Inc.

Japan, Mexico, Pakistan, Sri Lanka, United States of America

Timeline & Enrollment

Phase 3

N/A

N/A

ICD-10 Classifications

COVID-19, virus identified
COVID-19, virus not identified
Coronavirus infection, unspecified site
Viral infection, unspecified
Rift Valley fever

Data Source

Sri Lanka Clinical Trials Registry

SLCTR_2021_026

Non-Device Trial